Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2000
10/17/2000US6133271 Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
10/17/2000US6133270 Isothiazolones and pharmaceutical formulations
10/17/2000US6133269 Polymorphic form of doxazosin mesylate (form II)
10/17/2000US6133268 1,4-disubstituted piperazines
10/17/2000US6133267 Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications
10/17/2000US6133265 Treating physiological disorders associated with an excess of neuropeptide y, such as eating disorders, e.g., obesity, bulimia, and certain cardiovascular diseases, e.g., hypertension
10/17/2000US6133264 Carbostyril derivatives for inhibiting skin erythema and/or skin pigmentation
10/17/2000US6133262 3-aminobenzo(b)thiophene derivatives
10/17/2000US6133261 Amino acid derivatives useful to treat stroke
10/17/2000US6133260 Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases
10/17/2000US6133259 Diagnosis of alzheimer's disease
10/17/2000US6133258 Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative
10/17/2000US6133257 Fused polycyclic 2-aminopyrimidine derivatives
10/17/2000US6133255 Useful in the therapy of deleterious mental states; psychological disorders
10/17/2000US6133254 Treatment of autoimmune diseases
10/17/2000US6133253 3-Pyridyl enantiomers and their use as analgesics
10/17/2000US6133252 Fungicides for the control of take-all disease of plants
10/17/2000US6133251 First stage daily dosage portion is natural estrogen, second stage daily dosage portion is a combination of natural estrogen and natural or synthetic gestogen, third stage daily dosage portion is natural estrogen, fourth dosage is placebo
10/17/2000US6133250 Oral 1α-hydroxyprevitamin D in methods for increasing blood level of activated vitamin D
10/17/2000US6133249 Phospholipid and propylene glycol based lubricant
10/17/2000US6133248 Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
10/17/2000US6133247 Method of detecting lung disease
10/17/2000US6133243 Administering to tumor a complex consisting of liposomal viral dna, said viral dna being purified adenoviral dna not in an expression vector and lacking expressed viral oncoprotein that binds to functional p53 tumor suppressor protein
10/17/2000US6133241 Bioflavonoids as plasma high density lipoprotein level increasing agent
10/17/2000US6133240 Tetrahydronapthalene derivatives and their therapeutic use
10/17/2000US6133238 Tetrahydrofurans
10/17/2000US6133198 Administering bioassimilable boron compounds to plants infected with viroids in an amount to provide in the plants a boron concentration of 100-150 ppm and protect them from the effect of subviral infections
10/17/2000US6133032 Antisense modulation of PI3 kinase p110 beta expression
10/17/2000US6133031 Antisense inhibition of focal adhesion kinase expression
10/17/2000US6133024 Recombinant vector which codes for an rna capable of forming a triple helix with target nucleic acid; for transcription of the rna in target cells
10/17/2000US6133006 Nucleotide sequence coding an enzmatic polypeptide associated with signal transduction; for the diagnosis and treatment of osteoporosis, inflammation, skin disorders, asthma, nervous system disorders, cancer, eating disorders and infections
10/17/2000US6133005 Enzymatic protein; for the treatment of nervous system disorders associated with thamine vitamin deficiency
10/17/2000US6132980 Antibodies specific for TRP-2 a human tumor antigen recognized by cytotoxic T lymphocytes
10/17/2000US6132965 Detecting premature atherosclerosis in humans; screening humans for amplified levels of serum homocysteine and comparing to control
10/17/2000US6132962 Plasmid coding ribozyme; for the prevention of viral infection
10/17/2000US6132789 For vaccine formulations as adjuvants and/or delivery systems, to enhance immune response to immunogens in animal such as human
10/17/2000US6132776 Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing
10/17/2000US6132774 Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
10/17/2000US6132772 Extended-release solid oral dosage forms of drugs having low solubility in water
10/17/2000US6132771 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
10/17/2000US6132770 Multiple unit effervescent dosage forms comprising proton pump inhibitor
10/17/2000US6132768 Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
10/17/2000US6132767 Administering osmotic colonic evacuant containing a picosulfate
10/17/2000US6132760 Contains a therapeutically effective amount of testosterone and a delivery enhancing adjuvant comprising a terpene.
10/17/2000US6132759 Medicaments containing gelatin cross-linked with oxidized polysaccharides
10/17/2000US6132758 A loratadine and an aminopolycarboxylic acid or a salt thereof.
10/17/2000US6132757 Treatment of sexual dysfunction in certain patient groups
10/17/2000US6132754 Injecting said patient with solution of anticholinergic medications containing atropine, scopolamine and chlorpromazine; concomitantly prescribing anticholinergic medications and benzodiazepines
10/17/2000US6132753 Administering flosequinan to patients not taking hypotensives or not being treated with a nitrite or nitrate
10/17/2000US6132750 Particles of cross-linked proteins and polysaccharides with hydroxamic groups for chelating metals and their uses notably in cosmetics
10/17/2000US6132740 Resorcinol derivatives
10/17/2000US6132735 Reshaping of the cornea to reduce or eliminate refractive errors of the eye.
10/17/2000US6132733 Ringworm vaccine
10/17/2000US6132722 Recombinant antibody-enzyme fusion proteins
10/17/2000US6132715 Method of inhibiting biosynthesis of tumor necrosis factor
10/17/2000US6132706 Physiologically acceptable polymer comprising a backbone to which are attached guanidino groups, the polymer having a minimum molecular weight of 10,000.
10/17/2000US6131578 Inhibitors of UDP-G1cNAc:Ga1β1-3Ga1NAcαR β1-6 N-acetylglucosaminyltransferase (core 2 G1cNAc-T) and use of the inhibitors to prevent or treat cardiomyopathy associated with diabetes
10/17/2000US6131566 Metered dose inhaler for albuterol
10/17/2000US6131226 1,4-dihydropyridine compounds as bradykinin antagonists
10/17/2000CA2305893A1 Use of maduraphthalazine derivatives as inhibitors of proinflammatory cytokines
10/17/2000CA2202031C Condensed indan derivatives and salts thereof
10/17/2000CA2193497C Controlled release aqueous emulsion
10/17/2000CA2178752C N-terminally chemically modified protein compositions and methods
10/17/2000CA2177357C Pna-dna-pna chimeric macromolecules
10/17/2000CA2156726C Bisacodyl dosage form
10/17/2000CA2148071C Method of administering azithromycin
10/17/2000CA2134855C Gelatin powders with improved tabletability, color and odor characteristics
10/17/2000CA2116743C Swellable wound dressing materials
10/17/2000CA2114300C Quinoline or quinazoline derivatives, their production and use
10/17/2000CA2086179C Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses
10/17/2000CA2074533C 2-nitroimidazole derivative, production thereof, and radiosensitizer containing the same as active ingredient
10/17/2000CA2024694C Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
10/17/2000CA2022484C 1-(pyridinylamino)-2-pyrrolidinones, a process for their preparation and their use as medicaments
10/17/2000CA2006719C Antibacterial antiplaque oral composition
10/17/2000CA2001205C Antimicrobial quinolonyl lactams
10/17/2000CA1341123C Filamentous hemagglutinin of b. pertussis
10/15/2000CA2305940A1 Aminotriazol compounds, the process for preparing them and the pharmaceutical compositions containing them
10/15/2000CA2305825A1 Novel bioactivating substance
10/13/2000CA2305047A1 2-pyridinylguanidine urokinase inhibitors
10/12/2000WO2000060858A1 Time and location-driven personalized tv
10/12/2000WO2000060117A2 Prediction of risk of interstitial lung disease
10/12/2000WO2000060109A1 Amplification of cyp24 and uses thereof
10/12/2000WO2000060077A2 Compounds for therapy and diagnosis of lung cancer and methods for their use
10/12/2000WO2000059946A1 Hydroxymatairesinol in cancer prevention
10/12/2000WO2000059942A2 Human obesity protein binding protrein-2 homolog and uses thereof
10/12/2000WO2000059930A1 A method of treating cancer
10/12/2000WO2000059929A1 Macrocyclic peptides active against the hepatitis c virus
10/12/2000WO2000059922A1 14,15-.alpha.-methylene equilenine derivatives, methods for producing the same and medicaments containing them
10/12/2000WO2000059920A2 Orally active 7.alpha.-alkyl androgens
10/12/2000WO2000059919A1 ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION
10/12/2000WO2000059913A1 Novel thiazolobenzimidazole derivatives
10/12/2000WO2000059905A1 ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
10/12/2000WO2000059904A2 Compounds and methods to treat cardiac failure and other disorders
10/12/2000WO2000059901A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
10/12/2000WO2000059900A1 P38mapk inhibitor and uses thereof
10/12/2000WO2000059899A1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
10/12/2000WO2000059892A1 Pyrimidine compounds with pharmaceutical activity
10/12/2000WO2000059890A1 Tetrahydropyridazine derivatives
10/12/2000WO2000059889A1 α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES
10/12/2000WO2000059888A1 N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
1 ... 6228 6229 6230 6231 6232 6233 6234 6235 6236 6237 6238 6239 6240 6241 6242 6243 6244 6245 6246 6247 6248 ... 7860